Kymera Therapeutics (KYMR) Tops Q3 EPS by 1c

Kymera Therapeutics (NASDAQ: KYMR) reported Q3 EPS of ($0.82), $0.01 better than the analyst estimate of ($0.83). Revenue for the quarter came in at $3.74 million versus the consensus estimate of $10.34 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.

You May Also Be Interested In

• KeyBanc Downgrades Primoris Services Corporation (PRIM) to Sector Weight
• RBC Capital Starts Molina Healthcare (MOH) at Sector Perform
• CNH Industrial Capital prices $600 million in notes due 2031